Magnetar Financial LLC Raises Stock Position in Janux Therapeutics, Inc. $JANX

Key Points

• Magnetar Financial LLC increased its stake in Janux Therapeutics by 204.2% in Q1, owning a total of 41,055 shares valued at approximately $1.1 million.
• Analysts have a consensus rating of "Buy" for Janux Therapeutics, with an average price target of $86.90 per share.
• Janux Therapeutics reported a loss of ($0.55) EPS for the last quarter, falling short of analysts' expectations by $0.07.

Magnetar Financial LLC grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 204.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,055 shares of the company's stock after buying an additional 27,557 shares during the period. Magnetar Financial LLC owned approximately 0.07% of Janux Therapeutics worth $1,108,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Janus Henderson Group PLC raised its holdings in shares of Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock valued at $190,617,000 after acquiring an additional 1,038,996 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its stake in shares of Janux Therapeutics by 46.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock worth $188,246,000 after acquiring an additional 1,115,412 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Janux Therapeutics by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company's stock worth $61,524,000 after acquiring an additional 142,328 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Janux Therapeutics by 15.7% in the fourth quarter. Woodline Partners LP now owns 1,852,187 shares of the company's stock valued at $99,166,000 after purchasing an additional 251,924 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in Janux Therapeutics by 25.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,392,826 shares of the company's stock worth $37,607,000 after purchasing an additional 282,848 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Stock Up 1.8%

Shares of NASDAQ:JANX traded up $0.43 during midday trading on Friday, reaching $24.37. 159,876 shares of the company were exchanged, compared to its average volume of 917,297. The stock has a fifty day simple moving average of $24.51 and a two-hundred day simple moving average of $26.85. Janux Therapeutics, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $71.71. The firm has a market cap of $1.46 billion, a PE ratio of -13.58 and a beta of 2.84.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Guggenheim initiated coverage on Janux Therapeutics in a research note on Wednesday. They set a "buy" rating and a $72.00 target price for the company. Raymond James Financial started coverage on Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price for the company. Finally, Piper Sandler started coverage on Janux Therapeutics in a research report on Monday, August 18th. They issued an "overweight" rating and a $42.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $85.55.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.